341 related articles for article (PubMed ID: 29875343)
1. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
Schulz-Heddergott R; Moll UM
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
[TBL] [Abstract][Full Text] [Related]
2. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
3. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
4. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
Li D; Marchenko ND; Moll UM
Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
6. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
7. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
9. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
11. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
12. A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis.
Yue X; Zhao Y; Huang G; Li J; Zhu J; Feng Z; Hu W
Cell Discov; 2016; 2():16039. PubMed ID: 27807478
[TBL] [Abstract][Full Text] [Related]
13. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
14. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
Nat Commun; 2013; 4():2996. PubMed ID: 24356649
[TBL] [Abstract][Full Text] [Related]
15. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
16. Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S; Iwakuma T
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577483
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated mutant p53 drives the Warburg effect.
Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
Nat Commun; 2013; 4():2935. PubMed ID: 24343302
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival.
Alexandrova EM; Marchenko ND
Front Endocrinol (Lausanne); 2015; 6():53. PubMed ID: 25954247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
